A company developing male contraception technology.

Contraline

Contraline is a venture-backed, clinical-stage biotechnology company developing the first long-lasting, non-hormonal, and reversible male contraceptive. 

Virginia Catalyst

i.Lab at UVA

FundRx

Rhia Ventures

Shangbay Capital

MBX Capital

Metaplanet Holdings

Google Ventures

Graphene Ventures

Amboy Street Ventures

Smith Ventures

LAUNCH

The Syndicate.com

Founders Fund

Jaffray Woodriff

Jason Calacanis

Talent Resources Ventures

Join us in welcoming Robert S. Goldman to the Contraline team! 👏

We are so excited to share that Contraline's first in-human trial shows safety with 12-month efficacy signals of the ADAM™ male contraceptive!

Read more about it here:
https://lnkd.in/gZ8KhMhi

Contraceptives should fit seamlessly into our lives. Don't you think?

Last week, our CEO Kevin Eisenfrats  and CTO  Yelena Tropsha, PhD attended and presented at the 4th International Congress on Male Contraception (ICMC) at Rockefeller University in New York. The conference showcased that the field has advanced significantly with three novel male contraceptive methods now in the clinic. Contraline’s presentation discussed the journey of developing our vas-occlusive implant, ADAM, from concept to human trials.

We celebrate all of the researchers who attended ICMC and choose to work on male contraception every day; together, we are on the brink of a cultural shift in shared reproductive responsibility.

Did you catch our CEO, Kevin Eisenfrats, on the Medsider podcast today?

Kevin shared the story of founding Contraline and lessons learned along the way. Here are some of the topics that were discussed:

💡 The history of male contraception
📚 Transitioning from academia to entrepreneurship
 🏃 Setting the right milestones and executing quickly
💰  Grants vs. fundraising in the early days of the company
🚀  Getting a diverse set of investors around the table such as MBX Capital, Founders Fund, GV (Google Ventures), and Jason Calacanis
🌎  Creative ways of engaging your future customers and stakeholders

Thank you Scott Nelson for featuring Contraline on the pod! 

Blog:
https://lnkd.in/eMhN8rmk

Listen on Spotify:
https://lnkd.in/eejph4fE

This week our CEO Kevin Eisenfrats joined some of our investors, partners, friends and other healthcare industry leaders at Fortune Brainstorm Health.  It was exciting to see advancing male reproductive health as one of the hot topics on stage. As quoted in the Fortune article:

"Still, the $30 billion global fertility industry overwhelmingly caters to women, according to Grand View Research—just a small sliver is targeted toward men. That’s also reflected in the social understanding of infertility, which is commonly believed to be a women’s issue."

"We actually call the male partner the ‘silent partner,’” said Dr. Brian A. Levine, MD, MS, FACOG, founding partner and practice director at CCRM Fertility of New York. In a common scenario, he said, a woman having trouble conceiving would undergo a battery of tests, get a clear bill of health on all of them, and come to him puzzled—at which point he tells them to get their boyfriend or husband tested. “And the question is always, ‘why?’” he added. “What we have is an education problem here.”

Thank you Fortune Brainstorm team for a great couple days!




Ft: Alice Zheng, Pita Navarro, Helene Servillon 🇵🇭, Martin Sandgren, Ariel Kramer, Neel Shah, Khaled Kteily, Pamela Pure, Deena Shakir

CONT

COM:CONTRALINE

Contraline

locale

market

industry

website

linkedin

investor of

Metrics